Pharsight

Drugs that contain Daprodustat

1. Jesduvroq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11643397 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US8324208 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Dec, 2028

(4 years from now)

US11117871 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US11649217 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 01, 2028

NCE-1 date: 01 February, 2027

Market Authorisation Date: 01 February, 2023

Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia

Dosage: TABLET;ORAL

More Information on Dosage

JESDUVROQ family patents

Family Patents